Acute Leukemias

Acute Leukemias

A collection of features and news articles published in ASH Clinical News related to acute leukemias.

FDA Expands Ivosidenib’s Indication to Newly Diagnosed AML

On May 2, the U.S. Food and Drug Administration (FDA) approved an expanded indication for the IDH1 inhibitor ivosidenib to include the treatment of...

Medicare Payments for CAR T-Cell Therapy May Be on the Rise

Medicare beneficiaries with relapsed or refractory leukemia and lymphoma may soon have another treatment option. At least, that’s the hope of officials at the...

International Partnerships Lead to Strides in Pediatric Leukemia in El Salvador

Although acute lymphocytic leukemia (ALL) is relatively rare, it is the most common cancer diagnosed in children, representing approximately one-quarter of cancers diagnosed in...

The Year in FDA Approvals

In the past year, the U.S. Food and Drug Administration (FDA) approved several therapies for the treatment of myeloid malignancies, including the first treatment...

New Treatment Options Lead to New Questions in Acute Myeloid Leukemia

For the past 40 years, the standard remission induction treatment for patients with newly diagnosed acute myeloid leukemia (AML) who are candidates for intensive...
On location

Non-Engineered T Cells to Prevent or Treat Relapse in Post-Transplant AML/MDS

Infusion with “non-engineered” adoptive T-cell products induced responses in select patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) who had undergone allogeneic...
On location

RADIUS: Midostaurin Reduces Post-Transplant Relapse Risk in FLT3-Mutated AML

Post-transplant maintenance therapy with midostaurin was safe and reduced relapse risk in patients with FLT3-mutated acute myeloid leukemia (AML), according to findings from the...
On location

Prognostic Significance of Post-Transplant MRD Varies Based on Conditioning Regimen in ALL

Assessment of measurable residual disease (MRD) prior to allogeneic hematopoietic cell transplantation (alloHCT) is an established important prognostic factor in patients with acute lymphocytic...

Medicare Poised to Cover CAR T-Cell Therapy

Medicare may soon offer coverage of chimeric antigen receptor (CAR) T-cell therapy for patients with cancer, but with considerable restrictions that aim to rein...

Dasatinib Granted Approval for Pediatric Indication

The FDA expanded the indication of dasatinib, a second-generation tyrosine kinase inhibitor, to include the treatment of pediatric patients (≥1 year of age) with...
Advertisement

Current Issue

October 2019, Volume 5, Issue 12

This issue highlights the unintended consequences of fighting the nation’s opioid epidemic, considers the optimal frontline regimen for myeloma, and more.